Compare VRRM & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRRM | HRMY |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2016 | 2020 |
| Metric | VRRM | HRMY |
|---|---|---|
| Price | $13.46 | $30.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $25.90 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.7M | 693.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 347.37 | 7.97 |
| EPS | 0.17 | ★ 0.55 |
| Revenue | $132,969,000.00 | ★ $868,453,000.00 |
| Revenue This Year | $6.84 | $19.75 |
| Revenue Next Year | $6.88 | $12.88 |
| P/E Ratio | $78.68 | ★ $55.53 |
| Revenue Growth | 14.61 | ★ 21.51 |
| 52 Week Low | $12.83 | $25.52 |
| 52 Week High | $25.83 | $40.87 |
| Indicator | VRRM | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 35.41 | 46.73 |
| Support Level | N/A | $28.26 |
| Resistance Level | $15.55 | $30.96 |
| Average True Range (ATR) | 0.56 | 1.10 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 30.42 | 30.51 |
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.